Predicine will participate at the
Wednesday, Sept 19, 2018 | San Francisco
A key focus for Predicine is to show how ctDNA and ctRNA liquid biopsy can accelerate immuno-oncology drug development and deliver significant patient benefits.
On Sept 19, 2018, Zhixin Zhao, Ph.D., Associate Director at Predicine will represent our team at the Precision: Blood Cancer World R&D Summit; an annual event being held in San Francisco that brings together senior scientists and business leaders from pharma, biotech and academia, using extensive networking sessions to forge meaningful collaborations. The summit will cover the latest updates from the pipelines of small and large drug developers, and feature discussions around the latest trends in precision medicine through case studies from early discovery to development.
Dr. Zhao will be giving a keynote presentation introducing the Translational/Biomarker session on the second day of the event.
A key focus for Dr. Zhao will be showing how ctRNA + ctDNA liquid biopsy technology revolutionize and personalize how cancer patients are diagnosed and treated. This event provides an excellent opportunity to further inform, and closely collaborate with, a broad scientific community on the benefit of our comprehensive approach to the genomic profiling of cancer.
Submit your information below to request a meeting.
Predicine is a molecular information company that has developed a patented Gene RADAR technology, an RNA- and DNA-based liquid biopsy test for early cancer detection, disease monitoring and assessing minimal residual disease. With its integrated biomarker platform, vast data sets and advanced analytics, Predicine has partnered with 30+ biopharmas to support their clinical trials in US, EU, Australia and China. Predicine operates in US and China.
Schedule a meeting with us!
Date: Wednesday, September 19
Time: 8:15 am
Track: Translational/Biomarker track